BOLD compared with LYEL: revenue, margins and what each company keeps, and the suppliers and customers both name

BOLDBoundless Bio, Inc.

Mkt capRevenueRevenue

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

Compare

BOLDBoundless Bio, Inc.

LYELLyell Immunopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only BOLD 0

None

Shared 0

No disclosed counterparties: BOLD.

Only LYEL 11

—City of Hope Comprehensive Cancer Centerunlistedsupplier

—Dana Farber Cancer Instituteunlistedsupplier

—Innovative Cellular Therapeutics Holdings Limited and Innovative Cellular Therapeutics, Inc. (together, ICT)unlistedsupplier

—Miltenyi CliniMACS PRODIGY ®unlistedsupplier

7 more · LYEL chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

BOLDBoundless Bio, Inc.

2.41▲+0.57%· post 2.41· delayed

Mkt cap$54.8MRevenue—Revenue—

LYELLyell Immunopharma, Inc.

14.75▼−4.43%· post 15.26· delayed

After hoursNov 5 '26delayed

Mkt cap$378.1MRevenue$3,000Q3 FY26Revenue$36,000FY25

Compare

After hoursNov 5 '26delayed

BOLDBoundless Bio, Inc.

LYELLyell Immunopharma, Inc.

2.41▲+0.57%post 2.41delayed

Price

14.75▼−4.43%post 15.26delayed

$54.8M

Mkt cap

$378.1M

—

Revenue

$3,000Q3 FY26

—

Revenue

$36,000FY25

BOLD2.41▲+0.57%vsLYEL14.75▼−4.43%After hoursNov 5 '26delayed